Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of EBV gH/gL/gp42-Ferritin Vaccine With or Without gp350-Ferritin in Healthy Adults
NCT06908096Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Epstein-Barr virus infection and infectious mononucleosis (IM) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local and systemic reactogenicity signs and symptoms, Unsolicited adverse events and 1 more. Started May 2025; status: recruiting.
02
Conditions
Epstein-Barr virus infectioninfectious mononucleosis (IM)
Beyond the preview
Go deeper on NCT06908096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908096.